Cephalon Inc. Announces FDA Panel Advises Against Expanded Fentora Use.
Cephalon Inc. announced that a Joint Advisory Committee to the Food and Drug Administration voted not to recommend approval of an expanded label for Fentora. The panel expressed concerns about minimizing risks potentially associated with an expanded indication of Fentora. Fentora is used for the management of breakthrough pain in opioid-tolerant patients with cancer. An FDA action on the Fentora supplemental new drug application is expected by Sept. 13.
